Evidence map›Paper›PMID 31746818›Full record

ArticleOtology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology2020

Intratympanic Diltiazem-Chitosan Hydrogel as an Otoprotectant Against Cisplatin-Induced Ototoxicity in a Mouse Model.

James G Naples, Michael J Ruckenstein, Jarnail Singh, Brandon C Cox, Daqing Li

Open access · greenAbstract read
In one paragraph

Article in Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

James G NaplesDivision of Otolaryngology-Head and Neck Surgery, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Michael J RuckensteinDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Health System, Philadelphia, Pennsylvania.
Jarnail SinghDepartment of Pharmacology.
Brandon C CoxDepartment of Pharmacology.
Daqing LiDepartment of Otorhinolaryngology-Head and Neck Surgery, University of Pennsylvania Health System, Philadelphia, Pennsylvania.
University of Pennsylvania Health System · USBeth Israel Deaconess Medical Center · USSouthern Illinois University School of Medicine · US

Funding

A novel nanodialysis platform for inner ear detoxificationR01DC017144 · NIDCD · UNIVERSITY OF PENNSYLVANIA · PI LI, DAQING · 2019 to 2023
$2.4M
A Novel Regulated Nanohydrogel Delivery System for Targeted Inner Ear ApplicationR01DC014464 · NIDCD · UNIVERSITY OF PENNSYLVANIA · PI LI, DAQING · 2015 to 2019
$2.0M
Mechanisms that regulate hair cell survivalR01DC014441 · NIDCD · SOUTHERN ILLINOIS UNIVERSITY SCH OF MED · PI COX, BRANDON C. · 2016 to 2020
$1.6M
NIDCD NIH HHS R01 DC014441NIDCD NIH HHS R01 DC014464NIDCD NIH HHS R01 DC017144
6 · The paper itself

Abstract

hypothesisLocal administration of the calcium-channel blocker (CCB), diltiazem, via intratympanic (IT) chitosan-glycerophosphate (CGP) hydrogel will protect against cisplatin-induced ototoxicity.

backgroundCisplatin induces calcium-mediated apoptosis of cochlear outer hair cells (OHCs). Previous work demonstrated otoprotection and reduced auditory brainstem response (ABR) threshold shifts in a cisplatin-induced ototoxicity mouse model treated with multiple doses of IT diltiazem given in solution. Here, we evaluated the role of a single dose of IT CGP-diltiazem as a novel otoprotectant against cisplatin-induced ototoxicity.

methodsBaseline pure-tone and click-evoked ABRs were performed in control (IT CGP-saline, n = 13) and treatment (IT CGP-diltiazem 2 mg/kg, n = 9) groups of female CBA/J mice. A single dose of IT CGP hydrogel was administered just before intraperitoneal injection of cisplatin (14 mg/kg). On Day 7 posttreatment, ABRs were performed and cochleae were harvested. Hair cells were quantified using anti-myosin VIIa immunostaining and inner hair cell ribbon synapses were quantified using Ctbp2 immunostaining.

resultsThere was a statistically significant effect of treatment on click- and tone-evoked ABRs between groups. The mean threshold shifts were significantly reduced in both click- and tone-evoked ABRs on Day 7 in IT CGP-diltiazem treated mice compared with CGP-saline control mice. There were no significant differences in OHC counting between groups, but there appears to be an otoprotection against loss of synapses in the apical turn from IT CGP-diltiazem treated mice (p < 0.05).

conclusionsThis preliminary work suggests that IT CGP-diltiazem reduces ABR threshold shifts with possible mechanisms of protecting ribbon synapses in the setting of cisplatin-induced ototoxicity. More work is necessary to determine the mechanism underlying this otoprotection.

Indexed as

AnimalsAntineoplastic AgentsChitosanCisplatinDiltiazemDisease Models, AnimalDrug CarriersEvoked Potentials, Auditory, Brain StemFemaleHydrogelsInjection, IntratympanicMiceMice, Inbred CBAOtotoxicityAntineoplastic AgentsChitosanCisplatinDiltiazemDrug CarriersHydrogels

Identifiers

PMID31746818
PMCPMC6910999
OpenAlexW2985949901

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.